News

BEST Trial

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were...

Medtronic, Drug Filled Stent, clinical trial, ACC

Medtronic plc unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed...

Astron, Biotronik, BIOFLEX-I, trial, peripheral stents, CRT 2015

Biotronik announced the presentation of data from the iliac arm of the BIOFLEX-I clinical trial at the Cardiovascular Research Technologies (CRT) conference in Washington, D.C. The...

OrbusNeich, Combo Dual Therapy Stent, REMEDEE, EGO COMBO, JIM 2015

A three-year review of data on the Combo Dual Therapy Stent was presented at the Joint Interventional Meeting (JIM) 2015 in Rome. These data demonstrate the healing benefits of the Combo Dual...

Tryton Side Branch Stent, Pivotal IDE, bifurcation stent, bifurcation stent

Tryton Medical Inc. announced that results from the company’s pivotal clinical trial for the Tryton Side Branch Stent were published in the Journal of the American College of Cardiology...

A study being presented at the Society of Interventional Radiology’s annual scientific meeting says 3-D printing could become a powerful tool in customizing interventional radiology treatments to...

Cardinal Health announced plans to acquire Johnson & Johnson’s Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.94 billion in cash. 

Biotronik, DREAMS, BIOSOLVE-II trial, bioresorbable stent, magnesium

Biotronik announced the completion of enrollment in the BIOSOLVE-II trial — a clinical study investigating the safety and performance of DREAMS (DRug Eluting Absorbable Metal Scaffold).

MiStent SES, Micell Technologies, Europe, bioresorbable stents

Micell Technologies, Inc. announced the commercial availability of the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) in Europe. Stentys,...

Fantom, Reva Medical, Rutgers, bioresorbable stents

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time.

ASCERT, coronary bypass graft surgery, angioplasty, quality of life, value

Coronary bypass graft surgery commonly used to treat patients with coronary heart disease results in improved quality of life but also costs more than another often-used less invasive technique,...

Stents, BioMimics 3D, Veryan Medical, Biosensors International Group

Biosensors International Group has announced a distribution agreement with Veryan Medical Ltd. for BioMimics 3D, a nitinol stent with three-dimensional helical geometry designed for use in the...

Stents, Self-Apposing Stent, Stentys

Stentys announced that the Self-Apposing Stent has been implanted more than 10,000 times in patients worldwide

InspireMD, MGuard, CGuard, drug-eluting stent, MASTER II, CARENET, trials

InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114 patients were presented at a major...

bioresorbable stents

Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely expected to overtake metallic stents in the coming years if the data trend...

stents, bioresorbable, clinical trial, clinical study

Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. 

Wearable technologies, possible changes to stenting practices, state legislation on energy drinks, expanded use of minimally invasive heart repair procedures, and the development of a new class of...

Clinical trial/study, stents, venous therapies

Veniti Inc. announced that it has enrolled the first United States patients in the Virtus trial of the Veniti VICI Venous Stent System.

Boston Scientific, EVOLVE II, Synergy, bioresorbable stent

In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system met its...